
	Sara Bonstein joined Advaxis in March 2014 as the Chief Financial Officer, Senior Vice President. Sara has a decade of financial leadership experience in the life sciences industry with Eli Lilly &amp; Company, ImClone Systems, and Johnson &amp; Johnson. While at Eli Lilly &amp; Company, Sara was a Six Sigma Champion and Black Belt, leading multiple projects relating to clinical research, project management, finance, manufacturing, and commercial sales. Prior to her Six Sigma role, Sara held positions of increasing responsibility at ImClone (which was acquired by Eli Lilly in 2008) including Director of Finance where she led all budget and forecast activities for preclinical, clinical and manufacturing research and development, spanning over ten monoclonal antibody cancer therapeutics, including Erbitux, a cancer treatment with over $1.5 billion in annual sales. Prior to joining ImClone, Sara was a financial analyst at Johnson &amp; Johnson in both the Ortho McNeil Pharmaceuticals and Ortho Biotech Divisions of the company where she managed gross-to-net analysis and calculation for approximately $1.1 billion of pharmaceutical product sales. Sara is a 2004 graduate of Johnson &amp; Johnson&#39;s Financial Leadership Development Program. She holds a BS in Finance from The College of New Jersey and an MBA from Rider University.
